LAB Q2 2023 Earnings — Standard BioTools Inc. Revenue & Financial Results | Market Cap Arena

LABStandard BioTools Inc.

$388M

Q2 2023 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$28M+47.3% YoY

Gross Profit

$14M49.2% margin

Operating Income

-$17M-63.1% margin

Net Income

-$17M-61.6% margin

EPS (Diluted)

$-0.22

QoQ Revenue Growth

+10.1%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$10M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$356M

Total Liabilities

$469M

Stockholders' Equity

-$113M

Cash & Equivalents

$142M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$28M	$19M	+47.3%
Gross Profit	$14M	$4M	+207.3%
Operating Income	-$17M	-$39M	+54.8%
Net Income	-$17M	-$64M	+73.2%

Revenue Segments

Product And Service

$27M36%

Product

$22M28%

Instruments

$12M15%

Consumables

$10M13%

Service

$6M8%

Product and Service, Other

$180,0000%

Geographic Segments

EMEA

$11M41%

Americas

$10M38%

Asia Pacific

$6M21%